The research conducted by Gerald Soff MD has focused on the basic science and applied translational research in the field of angiogenesis. Specifically, he has been studying the protein, angiostatin, a naturally occurring inhibitor of angiogenesis. His laboratory has determined how angiostatin is generated, and this has allowed for production of the protein for animal research. Further studies have indicated mechanisms of action of angiostatin at the molecular and biochemical levels. Recently, he has begun studies on the direct in vivo generation of angiostatin in mice and cancer patients as a means of suppression of cancer growth and metastasis.
Additional studies are on other novel, naturally occurring angiogenesis inhibitors.
These include elements of the fibrinolytic pathway, including plasmin and plasminogen activator inhibitors, their substrates and products. Dr. Soff's research program thus offers a range of basic molecular and cell biological studies in angiogenesis, as well as translational research opportunities. The Mechanism of Cancer-Mediated Conversion of Plasminogen to the Angiogenesis Inhibitor, Angiostatin. Proc Nat Acad Sci. Angiostatin and Radiation Target the Tumor Vasculature.